]DPA-714 were investigated in rats, baboons, and humans. Whole-body PET experiments showed a high uptake of radioactivity in the kidneys, heart, liver, and gallbladder. The liver was a major route of elimination of [ 18 F]DPA-714, and urine was a route of excretion for radiometabolites. In rat and baboon plasma, high-performance liquid chromatography (HPLC) metabolic profiles showed three major radiometabolites accounting for 85% and 89% of total radioactivity at 120 minutes after injection, respectively. Rat microsomal incubations and analyses by liquid chromatography-mass spectrometry (LC-MS) identified seven metabolites, characterized as O-deethyl, hydroxyl, and N-deethyl derivatives of nonradioactive DPA-714, two of them having the same retention times than those detected in rat and baboon plasma. The third plasma radiometabolite was suggested to be a carboxylic acid compound that accounted for 15% of the rat brain radioactivity. 
5,7dimethylpyrazolo [1,5a] pyrimidin-3-yl)acetamide] is a new radioligand currently used for imaging the 18-kDa translocator protein in animal models of neuroinflammation and recently in humans. The biodistribution by positron emission tomography (PET) in baboons and the in vitro and in vivo metabolism of [ 18 F]DPA-714 were investigated in rats, baboons, and humans. Whole-body PET experiments showed a high uptake of radioactivity in the kidneys, heart, liver, and gallbladder. The liver was a major route of elimination of [ 18 F]DPA-714, and urine was a route of excretion for radiometabolites. In rat and baboon plasma, high-performance liquid chromatography (HPLC) metabolic profiles showed three major radiometabolites accounting for 85% and 89% of total radioactivity at 120 minutes after injection, respectively. Rat microsomal incubations and analyses by liquid chromatography-mass spectrometry (LC-MS) identified seven metabolites, characterized as O-deethyl, hydroxyl, and N-deethyl derivatives of nonradioactive DPA-714, two of them having the same retention times than those detected in rat and baboon plasma. The third plasma radiometabolite was suggested to be a carboxylic acid compound that accounted for 15% of the rat brain radioactivity. O-deethylation led to a nonradioactive compound and [ 18 F] fluoroacetic acid. Human CYP3A4 and CYP2D6 were shown to be involved in the oxidation of the radioligand. 
Introduction
The 18-kDa translocator protein (TSPO) is a heteropolymeric mitochondrial protein (Scarf, 2011) . TSPO is primarily located at outer mitochondrial membranes within transmembrane channels (Lacapère and Papadopoulos, 2003) that have many putative functions (Batarseh and Papadopoulos, 2010; Chelli et al., 2004; Rupprecht et al., 2010) . TSPO is now known to have a widespread distribution in the organism (Hirvonen et al., 2010) , and low levels of TSPO are found in the normal brain (Papadopoulos et al., 2006a) . TSPO is present in activated microglia (Myers et al., 1991) and to a lesser extent in astrocytes; hence, TSPO concentrations are found to be elevated in regions of brain inflammation arising from neurodegenerative disorders or stroke Lang, 2002; Papadopoulos et al., 2006b) . Positron emission tomography (PET) imaging of TSPO is therefore recognized as a clinical means to detect and investigate neuroinflammation. Among the PET radioligands that are clinically useful, [
11 C]PK11195 [N-methyl-N-(1-methylpropyl)-1-(2-chlorophenyl)isoquinoline-3-carboxamide] has been the most widely used (Hirvonen et al., 2010) . New candidate PET ligands for TSPO have recently been developed (for review, see Dollé et al., 2009 ), and these have been shown to have a higher brain uptake and a higher proportion of specific binding than [ 11 C]PK11195 (Lacapère and Papadopoulos, 2003; Chauveau et al., 2008) . In a recent study of several animal models of brain inflammation in our institution, [ 18 (Chauveau et al., 2009 F]DPA-714, N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl) 5,7 dimethylpyrazolo[1,5a]pyrimidin-3-yl)acetamide; G6P, glucose 6-phosphate; G6PDH, glucose-6-phosphate dehydrogenase; HPLC, high-performance liquid chromatography; LC-MS, liquid chromatography-mass spectrometry; LC-MS/MS, liquid chromatography-tandem mass spectrometry; NADP, nicotinamide adenine dinucleotide phosphate; NADPH, nicotinamide adenine dinucleotide phosphate reduced form; PET, positron emission tomography; SPE, solid-phase extraction; TSPO, 18-kDa translocator protein; VOI, volume of interest; PK11195: N-methyl-N-(1-methylpropyl)-1-(2-chlorophenyl)isoquinoline-3-carboxamide; pyrimidin-3-yl]-acetamide; PBR102: 2-(6-chloro-2-(4-(3-fluoroethoxy)phenyl)imidazo[1,2-a]pyridin-3-yl)-N,N-diethylacetamide; PBR111:2-(6-chloro-2-(4-(3-fluoropropoxy)phenyl)imidazo[1,2-a] pyridin-3-yl)-N,N-diethylacetamide. (Arlicot et al., 2012; Boellaard et al., 2011) .
To date, identification of the radiometabolites of [ 18 F] DPA-714 has yet to be published. This is an important step in the development of a new radiotracer since the radiometabolite corrected arterial input function for compartmental modeling is mandatory when no reference region (i.e., a region devoid of the target receptor) can be used. Furthermore, the presence of radiometabolites in the cerebral tissue could interfere with quantification. The quantification of TSPO distribution in the human brain requires the determination of the total plasma radioactivity concentration and the accurate determination of the non-metabolized fraction of [ 18 F] DPA-714 in plasma as a function of time. We have developed and validated a fast, sensitive, and convenient approach using solid-phase extraction (SPE) to quantify [ In addition, we demonstrate the equivalence of the time-activity curve at early time points of the PET study for the SPE procedure compared with our previous highperformance liquid chromatography (HPLC) method.
Predicting human metabolism before starting clinical studies is also critical. Therefore, the metabolism of nonradioactive DPA-714 was studied in vitro in microsomes (rat, baboon, and human), and the metabolism of [ 18 F] DPA-714 was studied ex vivo in rats and in vivo in rats and baboons.
Materials and Methods

Radiosynthesis
DPA-714 was labeled with fluorine-18 at its 2-fluoroethyl moiety using a tosyloxy-for-fluorine nucleophilic aliphatic substitution according to slight modifications of procedures already reported (Damont et al., 2008) 18 F] DPA-714 was checked in vitro in spiked rat or baboon plasma and in rat brain homogenate at 37°C. Baboon blood samples were taken immediately before the PET study. Plasma was prepared by centrifugation (5 minutes, 3000g, at room temperature). Six plasma samples (500 ml) were mixed with 20 kBq/ml [ 18 F]DPA-714. Three of these were extracted with 700 ml of CH 3 CN (98% recovery). The extracts were injected onto the radio-HPLC system, and the peak area corresponding to [ 18 F] DPA-714 was measured (time zero). The other three plasma samples were incubated at 37°C for 190 minutes before extraction (same extraction yield) and analysis. Similar experiments were performed with rat plasma. The stability of [ 18 F] DPA-714 in the rat brain was also checked according to the following procedure. The rat brain was excised, placed in 1 ml of aqueous 0.1 M potassium phosphate buffer (pH 7.4), and exposed for 20 seconds to an ultrasonic probe at 4°C. The brain homogenate was mixed with [ 18 F]DPA-714 (37 kBq). Three aliquots were extracted with CH 3 CN and analyzed as described previously. The remainder of the homogenate was incubated at 37°C for 180 minutes and then mixed with 2 ml of CH 3 CN and centrifuged at 3000g for 10 minutes. The supernatant was collected in three tubes then was directly analyzed by radio-HPLC.
Radiometabolites Analysis.
Baboons. During the PET experiments performed in isofluraneanesthetized baboons for the characterization of the kinetics of [ 18 F]DPA-714, 28 blood samples from each of the four baboons (1 ml; six independent PET experiments) were drawn from the femoral artery from 0 to 120 minutes after injection and immediately centrifuged at 4°C for 5 minutes at 3000g to obtain cell-free plasma. The radioactivity in the plasma samples (200 ml) was measured in a cross-calibrated gamma-counter (Cobra Quantum D5003; Perkin-Elmer, Courtaboeuf, France) and expressed in becquerels. All the values were corrected for fluorine-18 decay (109.7 minutes) until the injection time according to the following equation: +EXP(LN(2) × x/109.7) × y, where x represents the time of counting and y the radioactivity measured at that time.
For the radiometabolite analysis, arterial plasma samples (seven samples of 500 ml) were counted, deproteinated with 700 ml of acetonitrile, and centrifuged at 4°C for 2 minutes (3000g). The radioactivity in the resulting precipitate was counted for calculating the percentage recovery of radioactivity in the acetonitrile. The whole supernatant was injected onto the radio-HPLC system. Baboon urine was collected at the end of the PET experiment (T0 + 180 minutes) using a Foley catheter (NM Medical, Fretin, France). Urine sample (1 ml) was directly injected onto the same radio-HPLC system.
The analytical system consisted of a quaternary gradient pump, an ASI100T autosampler and a UVD170U UV-Vis detector (Dionex S.A., Courtaboeuf, France) online with a LB-509 radioisotope detector (MX Z500 cell; Berthold, La Garenne Colombes, France). [ Rats. Two rats were injected via a tail vein with 32.1 6 2.8 MBq [
18 F]DPA-714 and were sacrificed by decapitation 120 minutes later. Plasma samples were treated and analyzed as described earlier. The whole brain was excised, weighed, counted, and sonicated in 1 ml of acetonitrile on ice. The homogenate was centrifuged 10 minutes at 3000g. The pellet was resuspended and further sonicated in 1 ml of acetonitrile. After centrifugation of the second homogenate, the two extracts were pooled and concentrated by evaporation before analysis by radio-HPLC. The concentrations of [ 18 F]DPA-714 and its radiometabolites in tissues were expressed as a percentage of injected dose per gram of tissue (% ID/g). The radioactivity was also measured in the rat thighbone and in the bone marrow.
Quantification of [ 18 F] DPA-714 in Baboon Plasma by Solid-Phase Extraction. To develop a more sensitive, rapid, and convenient method to isolate the unchanged radiotracer from its radiometabolites, a method using only SPE was developed and compared with the radio-HPLC method, the latter being considered as the reference method. Five arterial plasma samples from each baboon (n = 3) were counted and analyzed by both radio-HPLC and SPE. A 60-mg HLB Oasis SPE cartridge (Waters) was conditioned with 1 ml of CH 3 OH and equilibrated with 5 ml of water. For the development of the method, the following procedure was used. Plasma samples (200 ml) were diluted to 400 ml with an aqueous solution containing 4% chlorhydric acid. The radioactivity was measured in the resulting solution, which was directly applied to the HLB cartridge (SPE fraction F1). The cartridge was then sequentially washed with 1 ml of H 2 O (fraction F2), then with a CH 3 CN/H 2 O solution (fraction F3). Several concentrations of CH 3 CN (15 concentrations between 25% and 39%) were tested for elution of the last fraction of radiometabolites. Then, 1 ml of a CH 3 CN/H 2 O 35/65 (v:v) solution was chosen for an optimal separation. [ F]DPA-714 were studied using whole-body PET imaging (HR+ PET tomography; Siemens Molecular Imaging, Knoxville, TN). Transmission scans (3 minutes per step, 5 or 6 steps according to the height of the animal) in two-dimensional mode were used for subsequent correction of attenuation of emission scans. Emission scans (in three-dimensional mode, at increasing durations from 1 to 4 minutes per step) were performed up to 90 minutes after the intravenous injection of 276 6 60 MBq (4.8 6 2.1 nmol) of [ 18 F]DPA-714. An experienced investigator drew volumes of interest (VOIs) over all organs that presented significant radioactivity on the earliest emission image for the liver, gallbladder, spleen, kidneys, and vertebral bodies. For the urinary bladder, a VOI was drawn on the last emission image.
In Vitro Metabolism of DPA-714
Chemicals. A D-glucose 6-phosphate disodium salt (G6P), b-nicotinamide adenine dinucleotide phosphate (NADPH), glucose-6-phosphate dehydrogenase (G6PDH) from yeast, formic acid, and bicinchoninic acid (BCA) protein assay kit was purchased from Sigma-Aldrich (St. Quentin Fallavier, France). Solvents used for HPLC and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses were from VWR (Val de Fontenay, France).
Liver Microsomes and cDNA-Expressed Human P450s. Microsomes from adult male Sprague-Dawley rats and from baboons were prepared by homogenization of liver samples over ice in a 0.1 M aqueous Tris-HCl buffer, pH 7.4, containing 1 mM EDTA and 0.2 M sucrose, followed by differential centrifugations according to Kremer's method (Kremers et al., 1981) . The total cytochrome P450 (P450) content was spectrophotometrically measured (Omura and Sato, 1964) . The total microsomal protein content was determined according to the BCA method with serum albumin as the standard. Human liver microsomes (pool of 10 individuals) and insect cell microsomes containing recombinant baculovirus cDNA-expressed human P450 (CYP1A2, CYP2A6, CYP2B6, CYP3A4, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 supersomes) characterized for their P450 content, protein content, and main specific catalytic activities were purchased from Gentest Corp (BD Biosciences, Le Pont-De-Claix, France). All microsomal fractions were stored at 280°C until used.
Typical Microsomal Incubation Procedure. The incubations contained 1 mg of microsomal proteins (rat, baboon, and human liver microsomes), a NADPH-generating system (5 mM G6P, 1 mM NADP + , G6P dehydrogenase 2 U), DPA-714 (100 mM), and 0.1 M aqueous potassium phosphate buffer (potassium dihydrogen phosphate and dipotassium hydrogen phosphate, pH 7.4) in a final volume of 1 ml. The reaction mixtures were preincubated for 2 minutes at 37°C before initiation of the reaction by the NADPH-generating system. The incubations were conducted in a 37°C water bath with gentle shaking for 15, 30, and 60 minutes. The reaction was stopped by the addition of an equal volume of acetonitrile. Samples were centrifuged at 4°C for 5 minutes at 9000g. The resulting supernatant was filtered (Vecta Spin Micro 0.2 mm; Whatman, Versailles, France), and 20 ml were analyzed by LC-MS/MS as described herein. Controls were incubated either without the NADPHgenerating system or without microsomes to ensure the stability of the tracer in the experimental conditions. The percentage of each metabolite was determined as a percentage of the total peak area. Enzymatic catalytic activities are expressed as a formation rate of each metabolite in nanomoles per milligram of microsomal proteins per minute (nmol metabolite/mg per minute).
Oxidation of DPA-714 by cDNA-Expressed Human P450s Isoforms. Microsomes from baculovirus-infected insect cells expressing human P450s and cell microsomes containing control activity were used (Gentest/BD Biosciences, Le Pont-De-Claix, France) to test their ability to oxidize DPA-714. The incubations included DPA-714 (50 mM), 20 pmol of P450, 1.3 mM NADP + , 3.3 mM G6P, G6PDH 2 U, and 0.1 M aqueous phosphate buffer, pH 7.4, in a final volume of 500 ml. The reaction proceeded for 30 minutes at 37°C and was stopped by the addition of 500 ml acetonitrile. Samples were centrifuged for 5 minutes at 10,000g, and 20 ml of the supernatants were analyzed by LC-MS/MS. Results are expressed as a percentage of the total peak areas for each metabolite (% of biotransformation).
Identification of DPA-714 Metabolites by LC-MS/MS. DPA-714 metabolites were analyzed by LC-MS/MS in microsomal extracts on a LCQ Deca XP+ ion trap mass spectrophotometer equipped with an electrospray source (Thermo Electron, Les Ulis, France). The HPLC system interfaced with the LCQ Deca XP+, which consisted of a LC Pump Surveyor (series 54949), PDA Surveyor (series 56470), and a Surveyor autosampler (series 55989, Thermo Electron, Les Ulis, France). Pressurized nitrogen was used as sheath gas with a flow rate of 25 units (arbitrary units for sheath gas pressure as defined by the manufacturer). The source voltage for electrospray ionization was 4.5 kV, and the capillary voltage was 38 V. The capillary temperature was 275°C. The separation of DPA-714 and its metabolites was performed using a reverse-phase Atlantis C18 column 2.1 Â 150 mm, 5 mm (Waters). The mobile phase consisted of A) H 2 O containing 0.05% formic acid and B) acetonitrile containing 0.05% formic acid. A linear gradient from 20 to 70% of B (80-30% of A) in 30 minutes was applied to the column at a flow rate of 200 ml/min. The whole output of the LC column was introduced into the photodiode array detector (190-600 nm) before the electrospray ionization probe of the LCQ Deca XP+ operated in the positive mode. In the full-scan MS acquisition mode, the instrument method was set up to detect ions in the range of m/z 50-500. The MS was set up in the MS/MS mode for acquiring, isolating with a mass width of 1 Da, and dissociating the ion m/z = 399 and its main metabolites by collision-induced dissociation in the ion trap using helium as the collision gas with an energy of 35%. Data acquisition and processing were performed with Xcalibur software (version 2.0) with the assistance of Mass Frontier software (version 4.0) for proposed fragmentation mechanisms (Thermo Electron). Fig. 2A) . The radioactivity measured in the acetonitrile protein precipitates (acetonitrile pellet) increased as a function of time and accounted for 17% of total plasma radioactivity at 120 minutes (Fig. 2B ). This radioactivity may be due to the presence of [ 18 (Fig. 2A) . The plasma concentrations of radioactivity and nonmetabolized [ 18 F] DPA-714 are presented in Fig.  2C (input function and metabolite-corrected input function).
Results
In Vivo Studies
In urine, the same radiometabolites as those detected in plasma were observed along with a very few amount (less than 2%) of [ 18 F] DPA-714 at 180 minutes. The radiometabolites eluted at 2.9, 5.9, and 8.2 minutes represented 51, 30, and 17% of total radioactivity, respectively (data not shown).
Major Route of [
18 F]DPA-714 Excretion in Baboons. The SUV max values obtained by whole body PET studies in baboons are summarized in Table 1 . High uptake of radioactivity was observed in TSPO-rich regions such as the heart (SUV max = 7.42) and parotid gland (SUV max = 1.93). The highest radioactivity was observed in the kidneys: SUV max = 12.7 at 10 minutes after injection, followed by a washout (SUV = 4.6 at 90 minutes after injection). Brain displayed low radioactivity in these normal baboons. Vertebral bodies showed also an uptake of radioactivity (SUV max = 1.99 at 90 minutes after injection) with a slow increase from the beginning until the end of the PET experiment. One route of excretion was the hepatobiliary system: SUV max in the gallbladder was 7.3 at 42 minutes after injection followed by the appearance of a large amount of radioactivity in the duodenal area. The other route of excretion was the urinary bladder with a SUV max of 6.5 at 90 minutes after injection.
Quantification of [ 18 F]DPA-714 and Its Radiometabolites by Solid-Phase Extraction. With the aim of developing a rapid, sensitive, and accurate quantification method of [ 18 F] DPA-714 and its radiometabolites in plasma for human quantitative imaging studies, we have developed an approach using only SPE. In baboon spiked plasma, the yield of extraction of non-metabolized radiotracer was 95 6 2% (n = 10). The limit of detection (LOD) and limit of quantification (LOQ) values were calculated as 1.2 and 1.8 Bq, respectively, compared with 55 and 145 Bq with HPLC. The mean total recovery of plasma-sample radioactivity with this method was 94 6 4% (n = 87). The time-activity course of SPE fractions are presented in Fig. 3A . The first fraction corresponded to proteins and radiometabolites that were not retained on the SPE column by hydrophobic and anionic interactions. Polar radiometabolites were (Fig. 3B) .
In Vivo Metabolism in Rats. Rat plasma sample analyses demonstrated the formation of three radiometabolites that had the same retention times as those detected in baboons. In plasma at 120 minutes after injection, the concentration of non-metabolized [ 18 F] DPA-714 was 15% of the total radioactivity (Fig. 4) . The main radiometabolite was suggested to be generated in plasma by further oxidation of hydroxylated radiometabolite(s) into a carboxylic acid derivative ([   18   F ]-M7, see identification of metabolites). This radiometabolite accounted for most of the plasma radioactivity. In the brain, at the same time, the concentration of total radioactivity was 2-fold higher than in plasma while that of non-metabolized [ 18 F ]DPA-714 was 11-fold higher than in plasma. This fraction represented 85% of the total brain radioactivity (Fig. 4) . The radiometabolite [
18 F]-M7 represented 15% of the total brain radioactivity, but the concentration of [ 18 F]-M7 was lower than in plasma (ratio of 0.4). The concentrations of the other radiometabolites found in plasma were quantitatively negligible in brain tissue. The radioactivity was also measured in the cortex of the thighbone and in the bone marrow at 120 minutes after injection. The results showed that 65% of the total bone radioactivity was in the bone marrow and 35% was found in the cortex of the thighbone.
In Vitro Studies
Species Comparison. Representative HPLC chromatograms of rat and human microsomal incubates are shown in Fig. 5A . Seven metabolites more polar than DPA-714 generated from oxidation by cytochromes P450 were detected in rat liver microsomal incubations by LC-MS (M1 to M6b; Fig. 5A ). The formation rates for each metabolite expressed in nmol/mg per minute were compared in three species (Fig. 5B) . Rat liver microsomes catalyzed the formation of seven metabolites M1 to M6b, with M1 and M3 being the most abundant (0.89 and 0.82 nmol/mg per minute) followed by M2, M4, and M5. In baboon liver microsomes, M4 and M5 were the predominant metabolites (0.46 and 0.64 nmol/mg per minute); in human liver microsomes, M3 and M4 predominated (0.45 and 0.57 The low mass of [ 18 F] DPA-714 administered to baboons prevented direct identification of metabolites in plasma by LC-MS. However incubating rat liver microsomes with DPA-714 and analysis by LC-MS identified two compounds having the same retention times as the radiometabolites detected in baboon plasma (Fig. 6 ). These two in vivo radiometabolites corresponded to N-dealkyl derivatives of [ 18 The peaks detected between 2 and 3 minutes by UV-detection corresponded to the solvent front. The third in vivo radiometabolite was not detected in microsomes. However, based on the metabolism of zolpidem, a closely related analog of DPA-714 (Pichard et al., 1995) , this highly polar compound was likely issued from further oxidation in plasma of a hydroxylated metabolite to generate a carboxylic acid derivative ([ 18 F]-M7) . From these findings, metabolic pathways for DPA-714 were proposed (Fig. 7) . The main oxidative metabolism of DPA-714 in liver microsomes likely occurred at the methyl of the pyrimidine moiety (hydroxylation), at the nitrogen (N-deethylation) and oxygen atom (O-deethylation). 
Metabolism of [ 18 F]DPA-714 in Rodents and Nonhuman Primates
Oxidation of DPA-714 by cDNA-Expressed Human P450s Isoforms. Microsomes expressing individual human P450s isoforms were used to test their ability to catalyze the oxidation of DPA-714. The fraction of each metabolite was determined using LC-MS (Fig. 8) . Human CYP3A4 exhibited the highest catalytic activity for the formation of M4 (9.3%, methyl-hydroxylation), M3 (7%, N-deethylation), and M5 (3.4%, O-deethylation) as in human liver microsomes (Table 2) . CYP2D6 was able to convert significantly DPA-714 into M5 (2.32%, O-deethylation). Other human P450s catalyzed the formation of one to four minor metabolites (less than 1%).
Discussion
The major findings of the present study are as follows. First, the main ways of elimination of [ 18 F] DPA-714 in baboons were the hepatobiliary (at least for the parent compound) and urinary (for radiometabolites) systems. Second, [ 18 F]DPA-714 was rapidly metabolized in vivo in rats and baboons into at least three radiometabolites. All of these were more polar than the native radioligand. Third, LC-MS-MS analysis of metabolites produced in vitro identified [M+H + ] ions consistent with hydroxyl, N-deethyl, and O-deethyl derivatives of DPA-714. Two of them, deethyl and deethyl-hydroxyl derivatives of DPA-714, have the same retention times than those detected in baboon plasma. Fourth, evidence indicates that a small amount of an acidic [ 18 F] metabolite enters the rat brain at late times but does not appear to display specific binding. Fifth, we have developed a rapid and easy method of quantification of the radioligand and its radiometabolites in plasma by SPE that may be useful in human quantitative PET studies.
The peripheral in vivo biodistribution of [ 18 F] DPA-714 by wholebody PET studies in baboons showed a high uptake of [ 18 F] DPA-714 in TSPO-rich peripheral regions such as the heart, spleen, and kidneys, in accordance with the data observed in rodents (Fookes et al., 2008; James et al., 2008) and recently in humans (Arlicot et al., 2012) . The other peripheral organs identified with moderate or high levels of radioactivity were involved in the metabolism or excretion of the tracer such as the liver and gallbladder. This radioactivity uptake has previously been shown to be specific by displacement experiments with nonlabeled DPA-714 . Time-activity curves in the gallbladder (data not shown) showed that the liver was a major route of elimination of [ 18 F]DPA-714 in baboons, with a finding also described in humans (Arlicot et al., 2012) . Urine was a route of excretion for radiometabolites. Indeed, a very small amount of residual [ 18 F] DPA-714 was found in the urinary samples at 120 minutes after injection. A vertebral uptake of radioactivity was also observed in baboons as well as in humans (Arlicot et al., 2012) .
The understanding of the metabolism of a candidate PET radioligand is important in establishing its value for quantitative imaging. Ideally, the candidate radioligand should not give rise to a radiometabolite that can enter the brain and significantly impair the identity of the PET signal. After we administered [ 18 (Arlicot et al., 2012) .
The low mass of radioligand administered to baboons (a few nanomoles) prevented direct identification of metabolites in plasma using LC-MS. However, incubating liver microsomes with DPA-714 and analyses by LC-MS identified at least seven metabolites (M1 to M6b) in rat and human, and four metabolites in baboon, two of them having the same retention times as the radiometabolites in baboon plasma. All were more polar than the native radioligand and in all except one, M5, the fluorine atom was preserved. At least four were the same in all three species, but the relative amount of individual metabolites differed between species. LC-MS data also demonstrated the formation by cytochrome P450 in rat, baboon, and human liver microsomes of seven main metabolites issued from N-deethylation ([ 18 (Pichard et al., 1995) , a closely structural analog of DPA-714, this radiometabolite was proposed to be generated by further oxidation of a hydroxylated radiometabolite(s) in plasma leading to the formation of a carboxylic acid derivative ([ 18 F]-M7). Human recombinant cytochrome P450 was used as a predictive model of human metabolism. CYP3A4 was found to be the major enzyme responsible for one hydroxylation reaction, N-deethylation, and O-deethylation of DPA-714 as shown in cDNA-expressed human P450 assays. CYP3A4 being the most abundant form in human liver, similar biotransformation of DPA-714 may occur in vivo. CYP2D6 was also clearly involved in the formation of O-deethylated DPA-714. The genetic polymorphism of human CYP2D6 may lead to large interindividual variability.
In vivo, O-deethylation led to the formation of two metabolites: a nonlabeled metabolite (M5) undetectable by radio-HPLC or LC-MS due to the low mass administered and [ 18 F] fluoroacetaldehyde, which is further converted to [ 18 F] fluoroacetate (or fluoroacetic acid) and defluorinated into free [ 18 F] fluoride. This transformation should not be quantitatively important, as shown by the low uptake of radioactivity in the bones (skull and vertebra). It should be noticed that red marrow is present in these bones and red marrow also contains TSPO (Kam Finally, a simplified method of quantification of [ 18 F] DPA-714 in plasma was developed using direct SPE to improve the estimation of a metabolite-corrected input function for future quantitative human PET studies. A similar exponential decrease of [ 18 F] DPA-714 in plasma was obtained with SPE and radio-HPLC, the latter considered as the reference method. Compared with radio-HPLC, the main advantages of the SPE method were the higher sensitivity (increased by a factor 80), faster processing (less than 30 minutes for more than 20 samples for SPE against 30 minutes for one time point by HPLC), the possibility of processing simultaneously multiple low radioactivity samples even at late times in the PET scan, and the low volume of plasma required. These advantages are particularly important in light of the decay of [ 18 F] -fluorine and the low activity injected to humans. Furthermore, this highly sensitive and specific procedure can be easily automated and used on a routine clinical basis. Another study by Katsifis et al. (2011) has also described a SPE method for measurement of intact TSPO ligands belonging to a closely related chemical family (PBR102 and PBR111), and they also found a good agreement between the SPE and HPLC methods.
In conclusion, [ 18 F ]DPA-714 is rapidly and extensively converted in vivo into several radiometabolites in rats and baboons. In vitro rat, baboon, and human microsomal studies demonstrate the formation by cytochrome P450 of hydroxylated and deethylated metabolites, some of which are detected in rat and baboon plasma. Secondary oxidation in plasma of a [ Errors on each measure were lower than 10% for metabolites representing more than 1% of total peak area and around 20% or less for metabolites representing more than 1% of total peak area.
